Why more biomanufacturers are re-evaluating how they source, prepare, and deliver cell culture media and buffers
Cell culture media and process buffers are fundamental to every biomanufacturing process. Yet while biologics manufacturing has evolved dramatically over the past decade, the way many organizations produce and manage these critical materials has remained largely unchanged.
Today, manufacturers are under increasing pressure to reduce costs, improve manufacturing flexibility, accelerate timelines, and bring therapies to patients faster. At the same time, supply chains remain unpredictable, production schedules change frequently, and expanding manufacturing capacity has never been more expensive.
As a result, organizations need to rethink long-established media and buffer manufacturing processes in search of greater efficiency, flexibility, and lower operating costs.
When it comes to cell culture media and buffers, most organizations focus on the purchase price. However, the true cost often extends far beyond the invoice. This is where point-of-use media manufacturing can be an advantage.
Whether your organization purchases ready-to-use liquid media or buffers from a supplier or manufactures these solutions internally from powders, there are often hidden costs throughout the process that are limiting efficiency and increasing risk.
The question is not simply:
How much does my media cost?
The better question is:
What does it cost to get media where I need it, when I need it?
How Are Your Media and Buffers Manufactured Today?
Most biomanufacturers rely on one of two approaches.
Option 1: Purchase Ready-to-Use Liquid Media and Buffers
For many manufacturers, liquid cell culture media and process buffers are produced by an external supplier, shipped to the facility, stored until needed, and then transported to manufacturing.
The process is familiar:
- Forecast media and buffer requirements months in advance
- Purchase large volumes of ready-to-use liquid solutions
- Wait for manufacturing and delivery
- Receive and inspect incoming solutions
- Store inventory until needed
- Transport it throughout the facility
- Dispose of expired inventory when production plans change
This approach simplifies internal operations, but convenience often comes with tradeoffs.
Organizations purchasing liquid media and buffers often face challenges such as:
- Long lead times
- High transportation costs
- Cold storage requirements
- Inventory carrying costs
- Media expiration risk
- Limited flexibility when production schedules change
To reduce supply chain risk, many organizations maintain additional inventory, increasing storage requirements and tying up additional labor.
Option 2: Manufacture Media and Buffers In-House
Other organizations purchase powdered media and buffers and manufacture it internally using mixing tanks, filtration systems, and dedicated personnel.
This approach can provide greater control over production and inventory. However, internal manufacturing introduces its own operational demands.
Common challenges include:
- Managing raw material inventories
- Dedicated mixing and filtration equipment
- Facility space requirements
- Labor-intensive preparation
- Batch-to-batch variability
- Cleaning and maintenance
- Validation activities
- Quality control testing
- Extensive documentation
As manufacturing scales, these requirements often scale as well.
The Hidden Costs Beyond the Media Itself
Whether media and buffers are purchased as a liquid or prepared internally, several cost drivers are frequently overlooked during planning and budgeting.
Inventory and Storage
Media often sits in storage before it is used.
This can require:
- Refrigerated storage
- Warehouse space
- Inventory management
- Material handling
- Quality oversight
As production volumes increase, these requirements continue to grow.
Supply Chain Risk
Lead times for custom media can range from weeks to months.
Production schedules, however, rarely remain fixed.
Engineering runs, process development activities, clinical demand, and commercial manufacturing frequently require adjustments.
When media and buffers have already been ordered or manufactured, schedule changes can lead to:
- Excess inventory
- Expedited purchases
- Delayed production
- Product waste
Labor and Documentation
Preparing, receiving, storing, and managing media and buffers require significant resources.
Activities often include:
- Material handling
- Documentation
- Equipment preparation
- Quality review
- Inventory tracking
- Batch record management
These activities create operational costs that may not be visible when evaluating media and buffer acquisition alone.
Facility Infrastructure
Organizations manufacturing media and buffers internally frequently dedicate valuable space to:
- Mixing tanks
- Filtration systems
- Storage areas
- Support equipment
- Validation activities
- Cleaning and maintenance procedures
As facilities grow, these infrastructure requirements can become increasingly expensive.
Quantifying the Cost of Media & Buffer Manufacturing: On-Demand vs. Traditional vs. Outsourced
Validation and Compliance
Every step involved in receiving, storing, transporting, preparing, filtering, and documenting cell culture media and process buffers must be validated and controlled as part of a GMP manufacturing process. Each validation activity requires planning, execution, documentation, review, and ongoing change control, all of which take valuable time and resources.
For organizations purchasing ready-to-use liquid media, validation activities may include:
- Receiving and inspection procedures
- Cold storage qualification and monitoring
- Material movement throughout the facility
- Inventory control processes
- Documentation and traceability
Organizations preparing media and buffers in-house often face an even greater validation burden, including:
- Vendor qualification
- Mixing equipment qualification
- Filtration validation
- Cleaning validation
- Process consistency studies
- Equipment maintenance
- Operator training and qualification
- Batch record verification
- Change control activities
Whether it’s receiving external liquid solutions or manual preparation, with so many steps (i.e., receiving, moving, staging, mixing, sampling, filtering, cleaning, and documentation), every manual handoff represents another opportunity for variability, human error, contamination, deviation, investigation, or delayed batch release.
As manufacturing operations grow more complex, validation efforts and their costs often grow alongside them.
The most expensive part of your media strategy may not be the media itself. It may be the labor, storage, infrastructure, inventory, validation, and operational complexity required to support it.
For organizations evaluating ways to improve efficiency, reduce costs, and increase manufacturing flexibility, it may be time to examine whether a different approach could deliver measurable value.
A Third Approach: Point-of-Use Media Manufacturing With Krakatoa® K500
Advances in automation and single-use manufacturing are creating a new option for biomanufacturers.
Rather than receiving large quantities of finished liquid media and buffers or operating traditional media preparation suites, point-of-use media manufacturing enables organizations to manufacture media and buffers directly where and when it is needed.
By replacing numerous manual preparation, handling, and documentation steps with a standardized automated workflow, point-of-use media manufacturing reduces operational complexity while simplifying validation activities and lowering overall manufacturing risk.
This approach reduces labor, shortens lead times, minimizes storage requirements, and aligns media production with actual manufacturing demand, while also lowering cost.
The Krakatoa® K500 was developed specifically to enable this point-of-use manufacturing model.
Using pre-filled powdered pods, automated closed single-use workflows, inline process monitoring, integrated sterile filtration, and electronic batch documentation, the Krakatoa® K500 manufactures 35 to 500 liters of GMP-grade cell culture media or process buffers in less than three hours with approximately 20 minutes of total operator interaction.
Instead of redesigning your manufacturing process around media and buffer availability, the Krakatoa® K500 allows media and buffer production to fit your manufacturing schedule.
| Buy Liquid | Prepare In-House | Krakatoa® K500 | |
|---|---|---|---|
| Lead Time | Weeks to Months | Days | <3 Hours |
| Cold Storage | High | Moderate | None |
| Facility Space | Moderate | High | Minimal |
| Labor | Low | High | Very Low |
| Documentation | Manual | Manual | Automated |
| Flexibility | Low | Moderate | High |
| Shelf Life | 1 Year (Liquid) | 1 Year (Liquid) | 2 Years (Pod) |
| Waste | Moderate | Moderate | Low |
| Operational Risk | Multiple manual handling steps | Multiple manual handling steps | Standardized automated workflow |
Cell culture media and buffers can account for up to 25–30% of your therapy’s total COGS.
By shifting to powder-based, on-demand manufacturing, the Krakatoa K500 substantially lowers media- and buffer-related costs and shortens lead time, while also helping to make therapies become more accessible to patients.
How the Krakatoa® K500 Addresses Traditional Challenges
Traditional media and buffer preparation introduces complexity throughout the manufacturing process.
The Krakatoa® K500 is designed to simplify many of these operational challenges.
| Challenge | Krakatoa® K500 |
| Extensive validation activities | Sterile pod and standardized automated workflow designed to reduce validation activities and operational risk |
| Weeks or months of lead time | Produce media and buffers on demand in less than 3 hours |
| Cold storage | Store stable powder pods at room temperature |
| Dedicated media preparation suites | Manufacture cell culture solutions at the point of use |
| Labor-intensive media and buffer preparation | Approximately 20 minutes of total operator interaction |
| Production schedules change | Produce only what is needed, when needed |
| Manual documentation | Automated electronic batch records |
For many organizations, the opportunity extends beyond reducing media and buffer costs. Point-of-use manufacturing can increase manufacturing flexibility, reduce operational complexity, optimize facility utilization, and strengthen supply chain resilience.
Will Your Media and Buffers Work on the Krakatoa® K500?
Many organizations are intrigued by the potential benefits of point-of-use media manufacturing but have one critical question:
Will my media formulation work?
The Krakatoa® K500 Remote Trial is designed to answer that question, in a low-risk way.
Our team will evaluate your existing formulation, manufacture your media or buffer on the Krakatoa® K500 system under controlled conditions, and ship it to you in liquid format. This provides a practical way to evaluate compatibility and performance prior to investing in the Krakatoa® K500.
Evaluate your existing formulation on the Krakatoa K500. Contact us to learn more about the Remote Trial.
Is Your Current Media and Buffer Sourcing Strategy Limiting Your Manufacturing Flexibility?
Organizations experiencing several of the following challenges may benefit from evaluating the Krakatoa® K500 for a point-of-use manufacturing approach.
For Organizations Purchasing Liquid Media
- Do you maintain significant safety stock inventory?
- Have media lead times impacted manufacturing schedules?
- Are storage requirements increasing?
- Do production changes create excess inventory or waste?
- Are transportation and logistics costs rising?
For Organizations Manufacturing Media and Buffers In-House
- Do you operate dedicated media preparation equipment?
- Is media and buffer preparation consuming valuable facility space?
- Are labor requirements increasing?
- Is documentation becoming more resource intensive?
- Are validation activities consuming significant time and effort?
For All Organizations
- Are you under pressure to reduce manufacturing costs?
- Do manufacturing schedules change frequently?
- Are you expanding production capacity?
- Are supply chain risks a growing concern?
- Would greater operational flexibility improve performance?
If you answered “yes” to several of these questions, Krakatoa® K500 may be worth exploring.
The Future of Media and Buffer Manufacturing Is Here
For decades, manufacturers have chosen between purchasing ready-to-use liquid cell culture media and process buffers or preparing it themselves.
Point-of-use cell culture media and process buffer manufacturing introduces a third option. One that combines the flexibility of on-demand production with the automation, consistency, and simplicity needed for modern biomanufacturing.
As manufacturing becomes more flexible, production schedules become increasingly dynamic, and organizations seek new ways to reduce costs, point-of-use media manufacturing is emerging as a smarter way to produce critical process solutions.
The Krakatoa® K500 was designed to help make that transition possible.
Discover how Krakatoa® K500 can help reduce cell culture media and buffer costs by 30-50% while transforming the way organizations manufacture critical solutions.
Ready to see if your media and buffers can be manufactured on the Krakatoa® K500? Contact Nucleus Biologics to learn more about the Krakatoa® K500 Remote Trial and begin evaluating your own formulation today.
